Endo International: from profit to seven straight losses.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Ireland
- Sources
- SEC filings (2013–2025), Stratrix's verified Decision Cases, market data and official economic statistics for Ireland
- Data as of
- November 2, 2026
- From profit to seven straight losses. Endo International lost money every year from 2013 to 2019: $9.7 billion in all. 2020 was its first profit in eight years: $0.2 billion.
- Left behind by its peers. From 2016 to 2023, its revenue shrank 50% in US dollars; the median among 636 large manufacturers grew 47%. It outgrew only 2% of them.
- Still smaller than it was. Revenue reached $2 billion in 2023, 50% below its 2016 peak of $4 billion.
- Leaders came and went. Endo International filed 29 leadership changes since 2016, more than 75% of large manufacturers (the median is 20).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $4 billion | −$3.3 billion | |
| 2017 | $3.5 billion | −$2 billion | |
| 2018 | $2.9 billion | −$1 billion | |
| 2019 | $2.9 billion | −$0.4 billion | |
| 2020 | $2.9 billion | $0.2 billion | |
| 2021 | $3 billion | −$0.6 billion | |
| 2022 | $2.3 billion | −$2.9 billion | |
| 2023 | $2 billion | −$2.4 billion |
As reported in its annual filings. Losses in red.
Has Endo International had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2021 | 3,103 | February 21, 2022 |
| 10-K for 2022 | 2,861 | February 27, 2023 |
| 10-K for 2023 | 2,931 | February 28, 2024 |
Job cuts, severance and restructuring
The company announced in November 2020 a set of strategic actions called the 2020 Restructuring Initiative to further optimize operations and increase efficiency, which it reports it has been progressing.
“In November 2020, we announced the initiation of several strategic actions, collectively referred to as the 2020 Restructuring Initiative, to further optimize operations and increase overall efficiency.” 10-K for 2021
The filing reports that 2021 amounts include a net pre-tax reversal of expense, mainly for severance costs that were avoided for employees who moved to buyers in certain site sales.
“Discontinued Operations and Note 4. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report, amounts in 2021 include a net pre-tax reversal of expense, primarily related to avoided severance costs for employees that transitioned to the purchasers in connection with certain site sales.” 10-K for 2021
The filing describes a 2020 restructuring initiative that included a workforce reduction, with employee separation costs recorded under it; the text supplied does not give the number of positions cut.
“endp:RestructuringInitiative2020Member 2020-11-01 2020-11-30 endp:position” 10-K for 2022
The company announced further actions to stop producing and selling QWO, which it calls the 2022 Restructuring Initiative, aimed at generating cost savings.
“In December 2022, we announced we would be taking certain additional actions to cease the production and sale of QWO ® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.” 10-K for 2023
| Fiscal year ended | Severance costs |
|---|---|
| 2016-12-31 | $60.2 million |
| 2017-12-31 | $53 million |
| 2018-12-31 | $31.7 million |
Endo International filed 6 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Endo International acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
BioSpecifics Technologies Corp.“As further described in Note 5. Acquisitions and Note 12. License and Collaboration Agreements in the Consolidated Financial Statements included in Part IV, Item 15 of this report, we completed our acquisition of BioSpecifics Technologies Corp., a Delaware corporation and a commercial-stage biopharmaceutical company (BioSpecifics) in December 2020.” 10-K for 2021 | acquisition | December 2020 | — |
retail generics business assets“For example, as further discussed in Note 3. Discontinued Operations in the Consolidated Financial Statements included in Part IV, Item 15 of this report, in 2021, we divested of certain assets related to our retail generics business, as well as certain associated liabilities.” 10-K for 2021 | divestiture | in 2021 | — |
Litha Healthcare Group Limited, certain assets acquired from Aspen Holdings, and Grupo Farmacéutico Somar, S.A.P.I. de C.V.“In 2017, we divested of both Litha Healthcare Group Limited and certain assets acquired from Aspen Holdings in October 2015 and Grupo Farmacéutico Somar, S.A.P.I. de C.V.” 10-K for 2021 | divestiture | 2017 | — |
manufacturing facilities and related assets in Chestnut Ridge, New York and Irvine, California“As a result of the sale of our manufacturing facilities and related assets in Chestnut Ridge, New York and Irvine, California, as further discussed in Note 3. Discontinued Operations in the Consolidated Financial Statements included in Part IV, Item 15 of this report, our reliance on third party manufacturers has increased and we are working with new third party manufacturers that we have not worked with before.” 10-K for 2021 | divestiture | — | — |
Auxilium Pharmaceuticals“Prior to Aralez, Dr. Tursi was Chief Medical Officer and Vice President of Clinical R&D at Auxilium Pharmaceuticals until its acquisition by Endo in 2015.” 10-K for 2021 | acquisition | 2015 | — |
Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc.“In May 2022, we announced that our EVL subsidiary had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2022 | agreed acquisition | In May 2022 | $35.0 million |
six development-stage RTU injectable product candidates from Nevakar Injectables, Inc.“• In May 2022, we announced that we had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2023 | acquisition | May 2022 | $35.0 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $30.4 million | $10.9 million | $93.6 million |
| 2017-12-31 | $0 | $223.2 million | — |
| 2018-12-31 | $0 | $70.4 million | — |
| 2019-12-31 | — | $6.6 million | — |
| 2020-12-31 | — | $6.7 million | — |
| 2021-12-31 | — | $30.3 million | — |
| 2022-12-31 | — | $41.4 million | — |
| 2023-12-31 | — | $5.1 million | — |
Deal filings since 2016
- 2024-04-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-01-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-04-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-04-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-04-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-05-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Endo International's competitors?
Who Endo International names
| Company | Named in |
|---|---|
| Amgen, Inc. | 2023 |
| Amneal | 2023 |
| Aurobindo Pharma Limited | 2023 |
| Jazz Pharmaceuticals plc | 2023 |
| Sandoz | 2023 |
| Takeda Pharmaceutical Company Limited | 2023 |
| Teva Pharmaceutical Industries Limited | 2023 |
| Viatris Inc. | 2023 |
In its own words
Amgen, Inc., Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Viatris Inc.
“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
Amneal, Aurobindo Pharma Limited, Sandoz, Teva Pharmaceutical Industries Limited
“Our major competitors, including Teva Pharmaceutical Industries Limited, Viatris, Sandoz, Aurobindo Pharma Limited and Amneal, among others, vary by product.” 10-K for 2023
What are Endo International's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| 70 Maple Avenue, LLC | Delaware |
| Actient Pharmaceuticals LLC | Delaware |
| Actient Therapeutics, LLC | Delaware |
| Anchen Incorporated | New York |
| Anchen Pharmaceuticals, Inc. | Delaware |
| Astora Women's Health Bermuda ULC | Bermuda |
| Astora Women's Health Ireland Limited | Ireland |
| Astora Women's Health Technologies Ireland | — |
| Astora Women's Health, LLC | Delaware |
| Auxilium International Holdings, LLC | Delaware |
| Auxilium Pharmaceuticals, LLC | Delaware |
| Auxilium US Holdings, LLC | Delaware |
| Bermuda Acquisition Management Limited | Bermuda |
| BioSpecifics Technologies LLC | Delaware |
| Branded Operations Holdings, Inc. | Delaware |
| CPEC LLC | Delaware |
| DAVA International, LLC | Delaware |
| DAVA Pharmaceuticals, LLC | Delaware |
| Endo Aesthetics LLC | Delaware |
| Endo Bermuda Finance Limited | Bermuda |
| Endo Designated Activity Company | Ireland |
| Endo Eurofin Unlimited Company | Ireland |
| Endo Finance IV Unlimited Company | Ireland |
| Endo Finance LLC | Delaware |
| Endo Finance Operations LLC | Delaware |
| Endo Finco Inc. | Delaware |
| Endo Generics Holdings, Inc. | Delaware |
| Endo Global Aesthetics Limited | Ireland |
| Endo Global Biologics Unlimited Company | Ireland |
| Endo Global Development Limited | Ireland |
| Endo Global Finance LLC | Delaware |
| Endo Global Ventures | Bermuda |
| Endo Health Solutions Inc. | Delaware |
| Endo India Holdings, LLC | Delaware |
| Endo Innovation Valera, LLC | New York |
| Endo Ireland Finance II Limited | Ireland |
| Endo LLC | Delaware |
| Endo Luxembourg Finance Company I S.a r.l. | Luxembourg |
| Endo Luxembourg Holding Company S.a r.l. | Luxembourg |
| Endo Luxembourg International Financing S.a r.l. | Luxembourg |
| Endo Management Limited | Ireland |
| Endo Par Innovation Company, LLC | Delaware |
| Endo Pharmaceuticals Finance LLC | Delaware |
| Endo Pharmaceuticals Inc. | Delaware |
| Endo Pharmaceuticals Solutions Inc. | Delaware |
| Endo Pharmaceuticals Valera Inc. | Delaware |
| Endo Procurement Operations Limited | Ireland |
| Endo TopFin Limited | Ireland |
| Endo U.S. Inc. | Delaware |
| Endo US Holdings Luxembourg I S.a r.l. | Luxembourg |
| Endo Ventures Aesthetics Limited | Ireland |
| Endo Ventures Bermuda Limited | Bermuda |
| Endo Ventures Cyprus Limited | Cyprus |
| Endo Ventures Unlimited Company | Ireland |
| Generics Bidco I, LLC | Delaware |
| Generics International (US) 2, Inc. | Delaware |
| Generics International (US), Inc. | New York |
| Generics International Ventures Enterprises LLC | Pennsylvania |
| Hawk Acquisition Ireland Limited | Ireland |
| Innoteq, Inc. | Delaware |
| JHP Acquisition, LLC | Delaware |
| JHP Group Holdings, LLC | Delaware |
| Kali Laboratories 2, Inc. | Delaware |
| Kali Laboratories, LLC | New Jersey |
| Luxembourg Endo Specialty Pharmaceuticals Holding I S.a r.l. | Luxembourg |
| Moores Mill Properties L.L.C. | Delaware |
| Operand Pharmaceuticals Holdco I Limited | Ireland |
| Operand Pharmaceuticals Holdco II Limited | Ireland |
| Operand Pharmaceuticals Holdco III Limited | Ireland |
| Operand Pharmaceuticals II Limited | Ireland |
| Operand Pharmaceuticals III Limited | Ireland |
| Paladin Labs Canadian Holding Inc. | Canada |
| Paladin Labs Inc. | Canada |
| Par Active Technologies Private Limited | India |
| Par Biosciences Private Limited | India |
| Par Formulations Private Limited | India |
| Par Laboratories Europe, Ltd. | England and Wales |
| Par Pharmaceutical 2, Inc. | Delaware |
| Par Pharmaceutical Companies, Inc. | Delaware |
| Par Pharmaceutical Holdings, Inc. | Delaware |
| Par Pharmaceutical, Inc. | New York |
| Par Sterile Products, LLC | Delaware |
| Par, LLC | Delaware |
| Quartz Specialty Pharmaceuticals, LLC | Delaware |
| Slate Pharmaceuticals, LLC | Delaware |
| Timm Medical Holdings, LLC | Delaware |
| Vintage Pharmaceuticals, LLC | Delaware |
From Exhibit 21 of the 10-K for 2023. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Endo International’s annual reports (10-K for 2023, 10-K for 2022, 10-K for 2021), as of 2024-03-06.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 64 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (0 with market data).
- Economic context: 6 measures for Ireland, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.